Edelweiss bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 3350 in its research report dated July 26, 2018.
Edelweiss' research report on Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories (DRRD) is our top pick in the large-cap pharma space and is also part of the Braveheart Series. Key assets of the company are progressing well and here is the update– 1) gSuboxone – Awaiting decision of the appeals court, which is expected in next few months; 2) gNuvaring – Minor query, expected launch in H1CY2019 vs H2FY2019 earlier; 3) gCopaxone – will submit response on earlier queries by August 2018 approval is expected in H2CY2019; 4) DFN02 – PDUFA date in January 2019, preparing for launch; 5) Srikakulam – Responded to all queries and USFDA response is expected; 6) Duvvada – Invited USFDA to re-inspect the plant.
There are multiple triggers in earnings in FY19, with full potential expected to be seen in FY20. Refer to our upgrade note. Maintain ‘BUY’ and TP of INR3,350.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Get Lok Sabha 2019 Live Election Results, constituency-wise tally, news, views and analysis
Follow our Lok Sabha Election Result Live Blog here.